{"id":{"repo_id":"usf","oai_identifier":"oai:digitalcommons.usf.edu:etd-12678"},"canonical_url":"https://search.ndltd.org/etd/usf/oai:digitalcommons.usf.edu:etd-12678","repository":{"repo_id":"usf","name":"University of South Florida","base_url":"https://digitalcommons.usf.edu/do/oai/"},"display":{"title":"Targeting Cancer with T Cells: Preclinical and In Silico Insights to Improve Immunotherapies","abstract":"T-cell–based immunotherapies are often constrained by limited trafficking and persistence in tumors and by functional exhaustion under chronic antigen exposure. This dissertation addresses these barriers through two distinct strategies: (i) preclinical studies testing how radiation therapy modulates tumor-infiltrating lymphocytes (TIL) therapy, and (ii) agent based modeling (ABM) to optimize treatment day treatment-free intervals (TFI) in T-cell engager (TCE) therapy. (i) In a human papillomavirus–positive (HPV⁺) head-and-neck cancer (HNC) model, a single local-dose of RT (8 Gy) delivered five days before tumor harvest increased the success and functional quality of ex vivo TIL outgrowth from tumor fragments, enriching polyfunctional CD8⁺ subsets. Delivering the same dose on the day of adoptive cell transfer (ACT) enhanced intratumoral accumulation of antigen-specific adoptively transferred T cells, improved control of both irradiated and shielded tumors, and generated durable tumor memory. (ii) To optimize TCE therapy in a B-cell acute lymphoblastic leukemia (B-ALL) setting, an ABM calibrated to published TCE data reproduced the reported advantage of a 7-day TFI over continuous exposure after 28 days, but showed that this advantage dissipates across a full 42-day clinical treatment cycle. Model-guided exploration of dosing schedules identified shorter, more frequent TFIs as superior for sustaining effector function and tumor control while limiting T cell exhaustion. Together, this work provides experimental and computational insights that may help refine the design of future T-cell–based therapies.","abstract_html":"T-cell–based immunotherapies are often constrained by limited trafficking and persistence in tumors and by functional exhaustion under chronic antigen exposure. This dissertation addresses these barriers through two distinct strategies: (i) preclinical studies testing how radiation therapy modulates tumor-infiltrating lymphocytes (TIL) therapy, and (ii) agent based modeling (ABM) to optimize treatment day treatment-free intervals (TFI) in T-cell engager (TCE) therapy. (i) In a human papillomavirus–positive (HPV⁺) head-and-neck cancer (HNC) model, a single local-dose of RT (8 Gy) delivered five days before tumor harvest increased the success and functional quality of ex vivo TIL outgrowth from tumor fragments, enriching polyfunctional CD8⁺ subsets. Delivering the same dose on the day of adoptive cell transfer (ACT) enhanced intratumoral accumulation of antigen-specific adoptively transferred T cells, improved control of both irradiated and shielded tumors, and generated durable tumor memory. (ii) To optimize TCE therapy in a B-cell acute lymphoblastic leukemia (B-ALL) setting, an ABM calibrated to published TCE data reproduced the reported advantage of a 7-day TFI over continuous exposure after 28 days, but showed that this advantage dissipates across a full 42-day clinical treatment cycle. Model-guided exploration of dosing schedules identified shorter, more frequent TFIs as superior for sustaining effector function and tumor control while limiting T cell exhaustion. Together, this work provides experimental and computational insights that may help refine the design of future T-cell–based therapies.","abstract_has_math":false,"creators":["Obertopp, Nina"],"institution":"University of South Florida","degree_name":"Doctor of Philosophy (Ph.D.)","degree_level":"Dissertation","degree_discipline":"Molecular Biosciences","degree_department":null,"school":null,"contributors":["Shari Pilon-Thomas, Ph.D.","Daniel Abate-Daga, Ph.D.","Dorina Avram, Ph.D.","Lawrence L. Stern, Ph.D.","Sungjune Kim, M.D., Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026-03-02T08:00:00Z","date_published":"2026-03-02T08:00:00Z","updated_at":"2026-11-19T08:52:02Z","subjects":["agent-based modeling","B-cell acute lymphoblastic leukemia","human papillomavirus","radiation therapy","T cell engager therapy","tumor-infiltrating lymphocyte therapy","head and neck squamous cell carcinoma","Immunology and Infectious Disease"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.usf.edu/etd/11375","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://digitalcommons.usf.edu/etd/11375","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.usf.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.usf.edu%3Aetd-12678","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Shari Pilon-Thomas, Ph.D.","Daniel Abate-Daga, Ph.D.","Dorina Avram, Ph.D.","Lawrence L. Stern, Ph.D.","Sungjune Kim, M.D., Ph.D."]},{"key":"dc:creator","label":"Author","values":["Obertopp, Nina"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2026-03-02T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Molecular Biosciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation","Ph.D."]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (Ph.D.)"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of South Florida"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["agent-based modeling","B-cell acute lymphoblastic leukemia","human papillomavirus","radiation therapy","T cell engager therapy","tumor-infiltrating lymphocyte therapy","head and neck squamous cell carcinoma","Immunology and Infectious Disease"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.usf.edu/etd/11375"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["T-cell–based immunotherapies are often constrained by limited trafficking and persistence in tumors and by functional exhaustion under chronic antigen exposure. This dissertation addresses these barriers through two distinct strategies: (i) preclinical studies testing how radiation therapy modulates tumor-infiltrating lymphocytes (TIL) therapy, and (ii) agent based modeling (ABM) to optimize treatment day treatment-free intervals (TFI) in T-cell engager (TCE) therapy. (i) In a human papillomavirus–positive (HPV⁺) head-and-neck cancer (HNC) model, a single local-dose of RT (8 Gy) delivered five days before tumor harvest increased the success and functional quality of ex vivo TIL outgrowth from tumor fragments, enriching polyfunctional CD8⁺ subsets. Delivering the same dose on the day of adoptive cell transfer (ACT) enhanced intratumoral accumulation of antigen-specific adoptively transferred T cells, improved control of both irradiated and shielded tumors, and generated durable tumor memory. (ii) To optimize TCE therapy in a B-cell acute lymphoblastic leukemia (B-ALL) setting, an ABM calibrated to published TCE data reproduced the reported advantage of a 7-day TFI over continuous exposure after 28 days, but showed that this advantage dissipates across a full 42-day clinical treatment cycle. Model-guided exploration of dosing schedules identified shorter, more frequent TFIs as superior for sustaining effector function and tumor control while limiting T cell exhaustion. Together, this work provides experimental and computational insights that may help refine the design of future T-cell–based therapies."]},{"key":"dc:title","label":"Title","values":["Targeting Cancer with T Cells: Preclinical and In Silico Insights to Improve Immunotherapies"]}]}],"canonical_facts":{"dc:contributor":["Shari Pilon-Thomas, Ph.D.","Daniel Abate-Daga, Ph.D.","Dorina Avram, Ph.D.","Lawrence L. Stern, Ph.D.","Sungjune Kim, M.D., Ph.D."],"dc:creator":["Obertopp, Nina"],"dc:date":["2026-03-02T08:00:00Z"],"dc:description":["T-cell–based immunotherapies are often constrained by limited trafficking and persistence in tumors and by functional exhaustion under chronic antigen exposure. This dissertation addresses these barriers through two distinct strategies: (i) preclinical studies testing how radiation therapy modulates tumor-infiltrating lymphocytes (TIL) therapy, and (ii) agent based modeling (ABM) to optimize treatment day treatment-free intervals (TFI) in T-cell engager (TCE) therapy. (i) In a human papillomavirus–positive (HPV⁺) head-and-neck cancer (HNC) model, a single local-dose of RT (8 Gy) delivered five days before tumor harvest increased the success and functional quality of ex vivo TIL outgrowth from tumor fragments, enriching polyfunctional CD8⁺ subsets. Delivering the same dose on the day of adoptive cell transfer (ACT) enhanced intratumoral accumulation of antigen-specific adoptively transferred T cells, improved control of both irradiated and shielded tumors, and generated durable tumor memory. (ii) To optimize TCE therapy in a B-cell acute lymphoblastic leukemia (B-ALL) setting, an ABM calibrated to published TCE data reproduced the reported advantage of a 7-day TFI over continuous exposure after 28 days, but showed that this advantage dissipates across a full 42-day clinical treatment cycle. Model-guided exploration of dosing schedules identified shorter, more frequent TFIs as superior for sustaining effector function and tumor control while limiting T cell exhaustion. Together, this work provides experimental and computational insights that may help refine the design of future T-cell–based therapies."],"dc:identifier":["https://digitalcommons.usf.edu/etd/11375"],"dc:subject":["agent-based modeling","B-cell acute lymphoblastic leukemia","human papillomavirus","radiation therapy","T cell engager therapy","tumor-infiltrating lymphocyte therapy","head and neck squamous cell carcinoma","Immunology and Infectious Disease"],"dc:title":["Targeting Cancer with T Cells: Preclinical and In Silico Insights to Improve Immunotherapies"],"thesis:degree_discipline":["Molecular Biosciences"],"thesis:degree_level":["Dissertation","Ph.D."],"thesis:degree_name":["Doctor of Philosophy (Ph.D.)"],"thesis:institution_name":["University of South Florida"]},"updated_at":"2026-11-19T08:52:02Z"}